Epidermal growth factor receptor in pancreatic cancer

Cancers

Volumn 3, Issue 2, 2011, Pages 1513-1526

  Oliveira Cunha, Melissa ^a   Newman, William G ^b   Siriwardena, Ajith K ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

EGFR; Expression; Mutation; Pancreatic cancer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GROWTH FACTOR; LUTEOLIN; MEMBRANE PROTEIN; PLACEBO; PROTEIN TYROSINE KINASE; QUERCETIN;

APOPTOSIS; CANCER CELL; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DINUCLEOTIDE REPEAT; DISEASE FREE SURVIVAL; DRUG TARGETING; EARLY DIAGNOSIS; EGFR GENE; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; INHIBITION KINETICS; INTRON; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 79959736865     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3021513     Document Type: Review

References (58)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. CA Cancer J. Clin. 2010, 60, 277-300.
2. Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; Falconi, M.; Pederzoli, P.; Pap, A.; Spooner, D.; Kerr, D.J.; Buchler, M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med.2004, 350, 1200-1210.
3. Neoptolemos, J.P.; Stocken, D.D.; Dunn, J.A.; Almond, J.; Beger, H.G.; Pederzoli, P.; Bassi, C.; Dervenis, C.; Fernandez-Cruz, L.; Lacaine, F.; Buckels, J.; Deakin, M.; Adab, F.A.; Sutton, R.; Imrie, C.; Ihse, I.; Tihanyi, T.; Olah, A.; Pedrazzoli, S.; Spooner, D.; Kerr, D.J.; Friess, H.; Buchler, M.W. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the espac-1 randomized controlled trial. Ann. Surg. 2001, 234, 758-768.
4. Inoue, S.; Tezel, E.; Nakao, A. Molecular diagnosis of pancreatic cancer. Hepato gastroenterology 2001, 48, 933-938.
5. Friess, H.; Kleeff, J.; Korc, M.; Buchler, M.W. Molecular aspects of pancreatic cancer and future perspectives. Dig. Surg. 1999, 16, 281-290.
6. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33, 369-385.
7. Mendelsohn, J.; Baselga, J. The egf receptor family as targets for cancer therapy. Oncogene 2000, 19, 6550-6565.
8. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The erbb signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000, 19, 3159-3167.
9. Iyer, R.; Thames, H.D.; Tealer, J.R.; Mason, K.A.; Evans, S.C. Effect of reduced egfr function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens. Radiother. Oncol. 2004, 72, 283-289.
10. Boonstra, J.; Rijken, P.; Humbel, B.; Cremers, F.; Verkleij, A.; van Bergen en Henegouwen, P. The epidermal growth factor. Cell Biol. Int. 1995, 19, 413-430.
11. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21, 2787-2799.
12. Citri, A.; Yarden, Y. Egf-erbb signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516.
13. Avraham, R.; Yarden, Y. Feedback regulation of egfr signalling: Decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12, 104-117
14. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
15. Ciardiello, F.; Tortora, G. Egfr antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
16. Barozzi, C.; Ravaioli, M.; D'Errico, A.; Grazi, G.L.; Poggioli, G.; Cavrini, G.; Mazziotti, A.; Grigioni, W.F. Relevance of biologic markers in colorectal carcinoma: A comparative study of a broad panel. Cancer 2002, 94, 647-657.
17. Korc, M.; Meltzer, P.; Trent, J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc. Natl. Acad. Sci. USA 1986, 83, 5141-5144.
18. Shimizu, N.; Kondo, H.; Gamou, M.A.; Behzadian, A.; Shimizu, Y. Genetic analysis of hyper production of epidermal growth factor receptors in human epidermoid carcinoma a431 cells. Somatic Cell Mol. Genet. 1984, 10, 45-53.
19. Barton, C.M.; Hall, P.A.; Hughes, C.M.; Gullick, W.J.; Lemoine, N.R. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J. Pathol. 1991, 163, 111-116.
20. Kwak, E.L.; Jankowski, J.; Thayer, S.P.; Lauwers, G.Y.; Brannigan, B.W.; Harris, P.L.; Okimoto, R.A.; Haserlat, S.M.; Driscoll, D.R.; Ferry, D.; Muir, B.; Settleman, J.; Fuchs, C.S.; Kulke, M.H.; Ryan, D.P.; Clark, J.W.; Sgroi, D.C.; Haber, D.A.; Bell, D.W. Epidermal growth factor receptorkinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 2006, 12, 4283-4287.
21. Jimeno, A.; Hidalgo, M. Pharmacogenomics of epidermal growth factor receptor (egfr) tyrosine kinase inhibitors. Biochim. Biophys. Acta 2006, 1766, 217-229.
22. Watanabe, T.; Hirono, T.; Koike, T.; Tsuchida, M.; Togashi, K.; Nakayama, K.; Yazawa, M.; Koyashiki, T.; Kanazawa, H. Registration of resected lung cancer in niigata prefecture. Jpn. J. Thorac. Cardiovasc. Surg. 2004, 52, 225-230.
23. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D.S. Epidermal growth factor receptor (egfr) signaling in cancer. Gene 2006, 366, 2-16.
24. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
25. Tzeng, C.W.; Frolov, A.; Frolova, N.; Jhala, N.C.; Howard, J.H.; Buchsbaum, D.J.; Vickers, S.M.; Heslin, M.J.; Arnoletti, J.P. Epidermal growth factor receptor (egfr) is highly conserved in pancreatic cancer. Surgery 2007, 141, 464-469.
26. Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba, II; Fong, K.M.; Lee, H.; Toyooka, S.; Shimizu, N.; Fujisawa, T.; Feng, Z.; Roth, J.A.; Herz, J.; Minna, J.D.; Gazdar, A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97, 339-346.
27. Sueoka-Aragane, N.; Imai, K.; Komiya, K.; Sato, A.; Tomimasu, R.; Hisatomi, T.; Sakuragi, T.; Mitsuoka, M.; Hayashi, S.; Nakachi, K.; Sueoka, E. Exon 19 of egfr mutation in relation to the ca-repeat polymorphism in intron 1. Cancer Sci. 2008, 99, 1180-1187.
28. Chi, D.D.; Hing, A.V.; Helms, C.; Steinbrueck, T.; Mishra, S.K.; Donis-Keller, H. Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (egfr) and pro alpha 2 (i) collagen (col1a2). Hum. Mol. Genet. 1992, 1, 135.
29. Brandt, B.; Meyer-Staeckling, S.; Schmidt, H.; Agelopoulos, K.; Buerger, H. Mechanisms of egfr gene transcription modulation: Relationship to cancer risk and therapy response. Clin. Cancer Res. 2006, 12, 7252-7260.
30. Liu, W.; Innocenti, F.; Chen, P.; Das, S.; Cook, E.H., Jr.; Ratain, M.J. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res. 2003, 9, 1009-1012.
31. Gebhardt, F.; Burger, H.; Brandt, B. Modulation of egfr gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics. Histol. Histopathol. 2000, 15, 929-936.
32. Buerger, H.; Gebhardt, F.; Schmidt, H.; Beckmann, A.; Hutmacher, K.; Simon, R.; Lelle, R.; Boecker, W.; Brandt, B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cyto genetic alterations and epithelial growth factor receptor expression. Cancer Res. 2000, 60, 854-857.
33. Etienne-Grimaldi, M.C.; Pereira, S.; Magne, N.; Formento, J.L.; Francoual, M.; Fontana, X.; Demard, F.; Dassonville, O.; Poissonnet, G.; Santini, J.; Bensadoun, R.J.; Szepetowski, P.; Milano, G. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (egfr) gene in head and neck cancer patients. Ann. Oncol. 2005, 16, 934-941.
34. Buisine, M.P.; Wacrenier, A.; Mariette, C.; Leteurtre, E.; Escande, F.; Aissi, S.; Ketele, A.; Leclercq, A.; Porchet, N.; Lesuffleur, T. Frequent mutations of the ca simple sequence repeat in intron 1 of egfr in mismatch repair-deficient colorectal cancers. World J. Gastroenterol. 2008, 14, 1053-1059.
35. Tzeng, C.W.; Frolov, A.; Frolova, N.; Jhala, N.C.; Howard, J.H.; Vickers, S.M.; Buchsbaum, D.J.; Heslin, M.J.; Arnoletti, J.P. Pancreatic cancer epidermal growth factor receptor (egfr) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann. Surg. Oncol. 2007, 14, 2150-2158.
36. Frolov, A.; Liles, J.S.; Kossenkov, A.V.; Tzeng, C.W.; Jhala, N.; Kulesza, P.; Varadarajulu, S.; Eloubeidi, M.; Heslin, M.J.; Arnoletti, J.P. Epidermal growth factor receptor (egfr) intron 1 polymorphism and clinical outcome in pancreatic adeno carcinoma. Am. J. Surg. 2010, 200, 398-405.
37. National Centre for Biotechnology Information (NCBI). Single nucleotide polymorphism database. Available online: Http://www.ncbi.nlm.nih.gov/projects/snp/ (assessed on 22 March 2011).
38. Wang, W.S.; Chen, P.M.; Chiou, T.J.; Liu, J.H.; Lin, J.K.; Lin, T.C.; Wang, H.S.; Su, Y. Epidermal growth factor receptor r497k polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin. Cancer Res. 2007, 13, 3597-3604.
39. Lassman, A.B.; Rossi, M.R.; Raizer, J.J.; Abrey, L.E.; Lieberman, F.S.; Grefe, C.N.; Lamborn, K.; Pao, W.; Shih, A.H.; Kuhn, J.G.; Wilson, R.; Nowak, N.J.; Cowell, J.K.; DeAngelis, L.M.; Wen, P.; Gilbert, M.R.; Chang, S.; Yung, W.A.; Prados, M.; Holland, E.C. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from north american brain tumor consortium trials 01-03 and 00-01. Clin. Cancer Res. 2005, 11, 7841-7850.
40. Zhang, W.; Stoehlmacher, J.; Park, D.J.; Yang, D.; Borchard, E.; Gil, J.; Tsao-Wei, D.D.; Yun, J.; Gordon, M.; Press, O.A.; Rhodes, K.; Groshen, S.; Lenz, H.J. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 2005, 5, 124-131.
41. Sasaki, H.; Okuda, K.; Shimizu, S.; Takada, M.; Kawahara, M.; Kitahara, N.; Okumura, M.; Matsumura, A.; Iuchi, K.; Kawaguchi, T.; Kubo, A.; Kawano, O.; Yukiue, H.; Yano, M.; Fujii, Y. Egfr r497k polymorphism is a favorable prognostic factor for advanced lung cancer. J. Cancer Res. Clin. Oncol. 2009, 135, 313-318.
42. Uegaki, K.; Nio, Y.; Inoue, Y.; Minari, Y.; Sato, Y.; Song, M.M.; Dong, M.; Tamura, K. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997, 17, 3841-3847.
43. Bloomston, M.; Bhardwaj, A.; Ellison, E.C.; Frankel, W.L. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 2006, 23, 74-79.
44. Tobita, K.; Kijima, H.; Dowaki, S.; Kashiwagi, H.; Ohtani, Y.; Oida, Y.; Yamazaki, H.; Nakamura, M.; Ueyama, Y.; Tanaka, M.; Inokuchi, S.; Makuuchi, H. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 2003, 11, 305-309.
45. Yamanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Beger, H.G.; Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993, 13, 565-569.
46. Arnold, D.; Peinert, S.; Voigt, W.; Schmoll, H.J. Epidermal growth factor receptor tyrosine kinase inhibitors: Present and future role in gastrointestinal cancer treatment: A review. Oncologist 2006, 11, 602-611.
47. Zhang, Y.; Banerjee, S.; Wang, Z.W.; Marciniak, D.J.; Majumdar, A.P.; Sarkar, F.H. Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of bxpc3 pancreatic cancer cells. Cancer Res. 2005, 65, 3877-3882.
48. Dong, M.; Nio, Y.; Guo, K.J.; Tamura, K.; Tian, Y.L.; Dong, Y.T. Epidermal growth factor and its receptor as prognostic indicators in chinese patients with pancreatic cancer. Anticancer Res. 1998, 18, 4613-4619.
49. Srivastava, A.; Alexander, J.; Lomakin, I.; Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Hum. Pathol. 2001, 32, 1184-1189.
50. Ueda, S.; Ogata, S.; Tsuda, H.; Kawarabayashi, N.; Kimura, M.; Sugiura, Y.; Tamai, S.; Matsubara, O.; Hatsuse, K.; Mochizuki, H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29, e1-e8.
51. Watanabe, M.; Nobuta, A.; Tanaka, J.; Asaka, M. An effect of k-ras gene mutation on epidermal growth factor receptor signal transduction in panc-1 pancreatic carcinoma cells. Int. J. Cancer 1996, 67, 264-268.
52. Marchetti, A.; Martella, C.; Felicioni, L.; Barassi, F.; Salvatore, S.; Chella, A.; Camplese, P.P.; Iarussi, T.; Mucilli, F.; Mezzetti, A.; Cuccurullo, F.; Sacco, R.; Buttitta, F. Egfr mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 2005, 23, 857-865.
53. Tsao, M.S.; Sakurada, A.; Cutz, J.C.; Zhu, C.Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F.A. Erlotinib in lung cancer- molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353, 133-144.
54. Immervoll, H.; Hoem, D.; Kugarajh, K.; Steine, S.J.; Molven, A. Molecular analysis of the EGFR-ras-raf pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006, 448, 788-796.
55. Lee, J.; Jang, K.T.; Ki, C.S.; Lim, T.; Park, Y.S.; Lim, H.Y.; Choi, D.W.; Kang, W.K.; Park, K.; Park, J.O. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and kras mutations on survival of pancreatic adenocarcinoma. Cancer 2007, 109, 1561-1569.
56. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O'Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
57. da Cunha Santos, G.; Dhani, N.; Tu, D.; Chin, K.; Ludkovski, O.; Kamel-Reid, S.; Squire, J.; Parulekar, W.; Moore, M.J.; Tsao, M.S. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National cancer institute of canada clinical trials group study pa.3. Cancer 2010, 116, 5599-5607.
58. Boeck, S.H.; Vehling-Kaiser, U.; Waldschmidt, D.; Kettner, E.; Marten, A.; Winklemann, C.; Klein, S.; Kojouharoff, G.; Jung, A.; Heinemann, V. Gemcitabine Plus Erlotinib (GE) Followed by Capecitabine (C) Versus Capecitabine Plus Erlotinib (CE) Followed by Gemcitabine (G) in Advanced Pancreatic Cancer (APC): A Randomized, Cross-Over Phase III Trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO); In ASCO Annual Meeting Proceedings, Chicago, IL, USA, 4-8 June 2010; J. Clin. Oncol. Chicago 2010, p. LBA4011